| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | $386.665 | $41.78B | Buy |
The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks
https://seekingalpha.com/article/4234239-week-san-francisco-2019-great-year-healthcare-stocks?source=feed_all_articles
Jan 18, 2019 -
0
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
http://www.zacks.com/stock/news/348354/aeries-aeri-eye-care-candidate-to-enter-clinical-studies?cid=CS-ZC-FT-348354
Jan 18, 2019 - Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.
0
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
http://www.zacks.com/stock/news/346497/biotech-stock-roundup-loxo-celg-gain-jp-morgan-healthcare-conference-in-focus?cid=CS-ZC-FT-346497
Jan 09, 2019 - It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
0
Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at 37th Annual J.P. Morgan Healthcare Conference (Transcript)
https://seekingalpha.com/article/4232079-regeneron-pharmaceuticals-inc-regn-ceo-leonard-schleifer-presents-37th-annual-j-p-morgan?source=feed_sector_transcripts
Jan 08, 2019 - Regeneron Pharmaceuticals Inc (NASDAQ:REGN) 37th Annual J.P. Morgan Healthcare Conference January 7, 2019 1:30 PM ET Company Participants Leonard Schleifer - Founder, President and Chief Executive Off
0
4 Biotechs That Are Potential Buyouts Post Celgene Deal
http://www.zacks.com/stock/news/346180/4-biotechs-that-are-potential-buyouts-post-celgene-deal?cid=CS-ZC-FT-346180
Jan 08, 2019 - We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
0
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
http://www.zacks.com/stock/news/346110/regeneron-sanofi-restructure-immuno-oncology-collaboration?cid=CS-ZC-FT-346110
Jan 07, 2019 - Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
0
Stocks making the biggest moves premarket: LUV, TSLA, NFLX, INTC & more
https://www.cnbc.com/2019/01/04/stocks-making-the-biggest-moves-premarket-luv-tsla-nflx-intc--more.html
Jan 04, 2019 - Names on the move ahead of the open.
8
Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund
https://seekingalpha.com/article/4230208-share-healthcare-biotech-gains-12-percent-yield-tekla-fund?source=feed_sector_healthcare
Dec 27, 2018 - The biotech sector not only has helped to discover cures to difficult medical problems but also has outperformed the broader market. Tekla Healthcare Investors (HQH) is a CEF which provides investors
0
Long-Term Outlook For Regeneron Pharmaceuticals
https://seekingalpha.com/article/4228998-long-term-outlook-regeneron-pharmaceuticals?source=feed_sector_healthcare
Dec 18, 2018 - REGN is retracing its levels from January 2018 after hitting lows in May and highs in September.Revenue continues to grow and REGN has a strong history of growth.Still, there are concerns and sell-off
0
5 Excellent GARP Picks With Cheap PEG Ratio
http://www.zacks.com/stock/news/343207/5-excellent-garp-picks-with-cheap-peg-ratio?cid=CS-ZC-FT-343207
Dec 17, 2018 - Although PEG ratio is categorized under value investing, this strategy follows the principles of both growth and value investing.
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| ZTS | Zoetis Inc. | NYSE | $88.3 | $42.55B |
| VRTX | Vertex Pharmaceuticals Incorporated | NASDAQ | $175.8 | $44.93B |
| SHPG | Shire plc | NASDAQ | $176.25 | $46.08B |
| ALXN | Alexion Pharmaceuticals, Inc. | NASDAQ | $117.77 | $26.25B |
| TEVA | Teva Pharmaceutical Industries Limited | NYSE | $23.43 | $23.86B |
REGN - Nasdaq
http://www.nasdaq.com/symbol/regn
Quote information directly from the exchange
SEC filings
Comparison
Ownership
Insiders
Institutions
Revenue/EPS
Competitors
Guru
Report
Analysts
Pre-market
Quote
Consultant
After hours
Transcripts
REGN - Google Finance
https://www.google.com/finance?q=REGN
Industry related info and international coverage
Summary
News
REGN - Bloomberg
http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=REGN
Original news and commentary from Bloomberg
Charts
Financials with pensions
Snapshot
Earnings
Transactions
People
Options